Intellus Advisors LLC Has $810,000 Stock Position in AbbVie Inc. $ABBV

Intellus Advisors LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 6.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,362 shares of the company’s stock after purchasing an additional 248 shares during the period. Intellus Advisors LLC’s holdings in AbbVie were worth $810,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ABBV. TD Capital Management LLC boosted its holdings in shares of AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after acquiring an additional 58 shares in the last quarter. Marshall & Sullivan Inc. WA acquired a new position in AbbVie during the 2nd quarter worth about $25,000. Spurstone Advisory Services LLC acquired a new stake in AbbVie in the 2nd quarter valued at about $28,000. Financial Gravity Companies Inc. bought a new position in shares of AbbVie in the second quarter worth about $36,000. Finally, Bear Mountain Capital Inc. lifted its position in shares of AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after purchasing an additional 173 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Up 2.9%

Shares of AbbVie stock opened at $236.12 on Monday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61. The company has a market capitalization of $417.31 billion, a P/E ratio of 112.44, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The business has a 50-day moving average of $226.81 and a two-hundred day moving average of $205.47.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the prior year, the business earned $3.00 EPS. AbbVie’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.9%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is presently 524.24%.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Guggenheim boosted their price objective on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Hsbc Global Res lowered AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Citigroup lowered their price objective on AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research report on Monday, November 3rd. Raymond James Financial set a $256.00 target price on shares of AbbVie in a research report on Monday, November 3rd. Finally, JPMorgan Chase & Co. lifted their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $241.85.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.